References
1. American College of Obstetricians, Gynecologists’ Committee on Practice Bulletins-Gynecology. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021;137(6):e100-e15.
2. Qin H, Lin Z, Vasquez E, Luan X, Guo F, Xu L. Association between obesity and the risk of uterine fibroids: a systematic review and meta-analysis. J Epidemiol Community Health. 2021;75(2):197-204.
3. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149(1):3-9.
4. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34(1):130-62.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-28.
6. Hebbar S, Chaya V, Rai L, Ramachandran A. Factors influencing endometrial thickness in postmenopausal women. Ann Med Health Sci Res. 2014;4(4):608-14.
7. Januzzi JL, Jr., Butler J, Sattar N, Xu J, Shaw W, Rosenthal N, et al. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care. 2021;44(1):210-6.
8. Yang Y, Yao S, Ding JM, Chen W, Guo Y. Enhancer-Gene Interaction Analyses Identified the Epidermal Growth Factor Receptor as a Susceptibility Gene for Type 2 Diabetes Mellitus. Diabetes Metab J. 2021;45(2):241-50.
9. Jeong IK, Byun JK, Noh J, Kim SW, Chung YS, Park TS, et al. Reference Ranges of Serum Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3: Results from a Multicenter Study in Healthy Korean Adults. Endocrinol Metab (Seoul). 2020;35(4):954-9.
10. Tak YJ, Lee SY, Park SK, Kim YJ, Lee JG, Jeong DW, et al. Association between uterine leiomyoma and metabolic syndrome in parous premenopausal women: A case-control study. Medicine (Baltimore). 2016;95(46):e5325.
11. Tseng CH. Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients. Ther Adv Endocrinol Metab. 2019;10:2042018819895159.
12. Ciavattini A, Delli Carpini G, Moriconi L, Clemente N, Orici F, Boschi AC, et al. The association between ultrasound-estimated visceral fat deposition and uterine fibroids: an observational study. Gynecol Endocrinol. 2017;33(8):634-7.
13. Sun K, Xie Y, Zhao N, Li Z. A case-control study of the relationship between visceral fat and development of uterine fibroids. Exp Ther Med. 2019;18(1):404-10.
14. Levey AS, Bilous R, Shlipak MG. CKD and Diabetes: What Can We Learn From Their Similarities and Differences? Am J Kidney Dis. 2016;67(3):360-3.
15. Takeda T, Sakata M, Isobe A, Miyake A, Nishimoto F, Ota Y, et al. Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. Gynecol Obstet Invest. 2008;66(1):14-7.
16. Chiang CH, Chen W, Tsai IJ, Hsu CY, Wang JH, Lin SZ, et al. Diabetes mellitus risk after hysterectomy: A population-based retrospective cohort study. Medicine (Baltimore). 2021;100(4):e24468.
17. Kang S, Park YM, Kwon DJ, Chung YJ, Namkung J, Han K, et al. Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus. Diabetes Metab J. 2022;46(4):578-91.
18. Oguz SH, Yildiz BO. An Update on Contraception in Polycystic Ovary Syndrome. Endocrinol Metab (Seoul). 2021;36(2):296-311.
19. Luo J, Manson JE, Urrutia RP, Hendryx M, LeBlanc ES, Margolis KL. Risk of Diabetes After Hysterectomy With or Without Oophorectomy in Postmenopausal Women. Am J Epidemiol. 2017;185(9):777-85.
20. Appiah D, Winters SJ, Hornung CA. Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2014;37(3):725-33.
21. Cermik D, Arici A, Taylor HS. Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma. Fertil Steril. 2002;78(5):979-84.
22. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab. 1994;78(5):1179-84.
23. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993;169(1):78-85.
24. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22(6):1696-704.
25. Padmanabhan S, Lee VW, McLean M, Athayde N, Lanzarone V, Khoshnow Q, et al. The Association of Falling Insulin Requirements With Maternal Biomarkers and Placental Dysfunction: A Prospective Study of Women With Preexisting Diabetes in Pregnancy. Diabetes Care. 2017;40(10):1323-30.
26. Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care. 2002;25(1):127-33.
27. Picard F, Wanatabe M, Schoonjans K, Lydon J, O’Malley BW, Auwerx J. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferation. Proc Natl Acad Sci U S A. 2002;99(24):15644-8.